Percutaneous Ablation of Hepatic Tumors at the Hepatocaval Confluence Using Irreversible Electroporation: A Preliminary Study

• Published in: Current oncology (Toronto) Vol. 29; no. 6; pp. 3950 - 3961
• Main Authors: Li, Tiankuan, Huang, Wei, Wu, Zhiyuan, Wang, Yong, Wang, Qingbing, Wang, Ziyin, Liu, Qin, Liu, Jingjing, Wang, Shenjie, Ding, Xiaoyi, Wang, Zhongmin
• Format: Journal Article
• Language: English
• Published: MDPI 31.05.2022; MDPI AG
• Subjects: hepatocaval confluence; irreversible electroporation; perivascular; tumor ablation
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol29060316

Background: Tumors at the hepatocaval confluence are difficult to treat, either surgically or ablatively. Methods: A retrospective longitudinal study on patients ineligible for thermal ablation who underwent computed tomography-guided IRE for hepatic tumors at the hepatocaval confluence was conducted. Factors analyzed included patient and tumor characteristics, IRE procedure details, treatment-related complications, and prognosis. Results: Between 2017 and 2021, 21 patients at our institute received percutaneous IRE. Of the 38 lesions, 21 were at the hepatocaval confluence. Complete ablation was achieved in all cases. Local and distant recurrence was observed in 4.8% (1/21) and 42.6% (9/21) of the ablated tumors, respectively. All postcava remained perfused at follow-up, except for 1 (4.8%) hepatic vein near the lesion found to be temporarily occluded and restored within 1 month. The ratio of the maximum diameter of ablation area at 1, 3, and 6 months post procedure compared to that immediately after IRE was 0.68 (0.50–0.84), 0.49 (0.27–0.61), and 0.38 (0.25–0.59), respectively. Progression-free survival of the patients with recurrence was 121 (range, 25–566) days. Four (19.0%) patients died at the end of follow-up with median overall survival of 451.5 (range, 25–716) days. Conclusions: IRE could be a safe and effective treatment for hepatic tumors at the hepatocaval confluence. This article provides valuable prognostic data; further clinical research is needed for better prognosis.